Company News
KangaBio's Novel Drug KGX105 Obtains IND Approval from CDE
2026-06-23
Company News
KangaBio Announces FDA IND Clearance for KGX105, AACR Acceptance of KGX101 Clinical Data Abstract, and Completion of Over $15 Million in Pre-A+ Financing
2026-03-03
Company News
Good News | KangaBio Wins First Prize at the 2024 Pudong New Area "Pearl Cup" Entrepreneurship Competition
2025-02-28
Company News
KGX101, an Innovative IL-12 Prodrug by Kangabio, Completes First Patient Dosing in China
2024-12-10
Media
Pharmaceutical Valley News – KangaBio’s Class 1 Novel Drug KGX101 Granted Clinical Trial Approval in China for the Treatment of Solid Tumors
2024-10-16
Media
IN³LAB Tech Dialogue —— Exclusive Interview with Dr. Weidong Jiang, Founder of KangaBio, an Innovative Biopharma Firm Focused on Novel Cancer Immunotherapies
2024-06-13
Company News
KangaBio present preclinical data of IL-12 prodrug KGX101 at AACR 2024
2024-04-10
Company News
KangaBio's IL-12 Prodrug KGX101: dosing of the first patient was completed
2023-12-13
Company News
KangaBio's new generation IL-12 prodrug has been approved for IND application in the United States
2023-10-26
Total 13 articles